mRNA-based therapeutics — developing a new class of drugs

Uğur Şahin(Johannes Gutenberg University Mainz), Özlem Türeci(Johannes Gutenberg University Mainz)

Nature Reviews Drug Discovery

September 19, 2014

10.1038/nrd4278

Cited by 2,383

Related Papers

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

|Nature|2020|2k

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

|Nature|2021|828

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

|Nature|2021|735

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

|Blood|2006|605

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

|Annals of Oncology|2021|357